Otsuka New Phase 3b Results for SIMTRIYO Improvements Across ADHD Symptoms, Anxiety
- New Phase 3b results demonstrated consistent improvements with centanafadine across ADHD and anxiety symptoms, executive function and emotional dysregulation, as assessed by both clinicians and patients
- Findings build on SIMTRIYO’s established ADHD clinical program in adults and pediatric patients, expanding its clinical profile in adults with comorbid anxiety disorders
- Data are part of 26 Otsuka-sponsored abstracts at the Congress, reflecting the company’s continued investment in advancing CNS and psychiatric neuroscience research
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.